Pair Name	Camptothecin, Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Down-regulation	Expression	ABCG2	hsa9429
	Down-regulation	Expression	MT1G	hsa4495
	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	SLC7A11	hsa23657
	Down-regulation	Expression	SQSTM1	hsa8878
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
	Huh-7	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0336
Result	The synergetic combination significantly increases lipid peroxidation and iron concentration, decreases TAC, GPX4 and GR activity, and reduces the expression of both Nrf2 and SLC7A11. The downregulation of Nrf2 expression has a vital role in the reduction of resistance mediators to sorafenib against HCC cells like (p62, MT1G, and ABCG2) and improves the cellular uptake of sorafenib. The current study provided evidence that Nrf2 inhibition by CPT improves sorafenib's sensitivity and reduces sorafenib's resistance via the augmentation of sorafenib's ferroptosis action.